310 related articles for article (PubMed ID: 29251528)
1. Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.
Xu J; Sun J; Wang P; Ma X; Li S
J Drug Target; 2018; 26(5-6):448-457. PubMed ID: 29251528
[TBL] [Abstract][Full Text] [Related]
2. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
[TBL] [Abstract][Full Text] [Related]
3. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents.
Xu J; Zhao W; Sun J; Huang Y; Wang P; Venkataramanan R; Yang D; Ma X; Rana A; Li S
J Control Release; 2018 Oct; 288():212-226. PubMed ID: 30223045
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy.
Sun J; Liu Y; Chen Y; Zhao W; Zhai Q; Rathod S; Huang Y; Tang S; Kwon YT; Fernandez C; Venkataramanan R; Li S
J Control Release; 2017 Jul; 258():43-55. PubMed ID: 28501705
[TBL] [Abstract][Full Text] [Related]
5. A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel.
Sun J; Chen Y; Li K; Huang Y; Fu X; Zhang X; Zhao W; Wei Y; Xu L; Zhang P; Venkataramanan R; Li S
Acta Biomater; 2016 Oct; 43():282-291. PubMed ID: 27422196
[TBL] [Abstract][Full Text] [Related]
6. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
Wan Z; Sun J; Xu J; Moharil P; Chen J; Xu J; Zhu J; Li J; Huang Y; Xu P; Ma X; Xie W; Lu B; Li S
Acta Biomater; 2019 May; 90():300-313. PubMed ID: 30930305
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer.
Luo Z; Xu J; Sun J; Huang H; Zhang Z; Ma W; Wan Z; Liu Y; Pardeshi A; Li S
Acta Biomater; 2020 Mar; 105():239-252. PubMed ID: 31958597
[TBL] [Abstract][Full Text] [Related]
8. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.
Sun JJ; Chen YC; Huang YX; Zhao WC; Liu YH; Venkataramanan R; Lu BF; Li S
Acta Pharmacol Sin; 2017 Jun; 38(6):823-834. PubMed ID: 28504251
[TBL] [Abstract][Full Text] [Related]
9. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
[TBL] [Abstract][Full Text] [Related]
11. Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.
Vijayaraghavalu S; Labhasetwar V
Drug Deliv Transl Res; 2018 Oct; 8(5):1289-1299. PubMed ID: 29947019
[TBL] [Abstract][Full Text] [Related]
12. Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.
Wu Z; Li S; Cai Y; Chen F; Chen Y; Luo X
Colloids Surf B Biointerfaces; 2020 May; 189():110741. PubMed ID: 32032928
[TBL] [Abstract][Full Text] [Related]
13. Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy.
Lu F; Hou L; Wang S; Yu Y; Zhang Y; Sun L; Wang C; Ma Z; Yang F
Drug Deliv; 2021 Dec; 28(1):963-972. PubMed ID: 34036867
[TBL] [Abstract][Full Text] [Related]
14. Platinum covalent shell cross-linked micelles designed to deliver doxorubicin for synergistic combination cancer therapy.
Zhu C; Xiao J; Tang M; Feng H; Chen W; Du M
Int J Nanomedicine; 2017; 12():3697-3710. PubMed ID: 28553108
[TBL] [Abstract][Full Text] [Related]
15. A multi-functional polymeric carrier for simultaneous positron emission tomography imaging and combination therapy.
Sun J; Sun L; Li J; Xu J; Wan Z; Ouyang Z; Liang L; Li S; Zeng D
Acta Biomater; 2018 Jul; 75():312-322. PubMed ID: 29885530
[TBL] [Abstract][Full Text] [Related]
16. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
[TBL] [Abstract][Full Text] [Related]
17. Redox-sensitive iodinated polymersomes carrying histone deacetylase inhibitor as a dual-functional nano-radiosensitizer for enhanced radiotherapy of breast cancer.
Zhu Z; Wu M; Sun J; Huangfu Z; Yin L; Yong W; Sun J; Wang G; Meng F; Zhong Z
Drug Deliv; 2021 Dec; 28(1):2301-2309. PubMed ID: 34730060
[TBL] [Abstract][Full Text] [Related]
18. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
Liu SQ; Tong YW; Yang YY
Biomaterials; 2005 Aug; 26(24):5064-74. PubMed ID: 15769542
[TBL] [Abstract][Full Text] [Related]
19. mPEGylated solanesol micelles as redox-responsive nanocarriers with synergistic anticancer effect.
Qin B; Liu L; Wu X; Liang F; Hou T; Pan Y; Song S
Acta Biomater; 2017 Dec; 64():211-222. PubMed ID: 28963017
[TBL] [Abstract][Full Text] [Related]
20. Exogenous Vitamin C-Triggered Surface Charge Conversion of pH/Reduction-Responsive Micelles for the Enhanced Tumor-Specific Activity of Loaded Doxorubicin.
Wu Z; Chen B; Gan Z; Chen F; Luo X
Mol Pharm; 2020 Mar; 17(3):954-964. PubMed ID: 31977226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
